Analysts Anticipate DelMar Pharmaceuticals Inc (DMPI) to Post ($0.11) EPS

Share on StockTwits

DelMar Pharmaceuticals Inc (NASDAQ:DMPI) has received a consensus broker rating score of 1.67 (Buy) from the three analysts that cover the stock, Zacks Investment Research reports. One analyst has rated the stock with a hold recommendation and two have given a strong buy recommendation to the company. DelMar Pharmaceuticals’ rating score has declined by 11.3% in the last 90 days as a result of a number of analysts’ ratings changes.

Brokers have set a twelve-month consensus target price of $7.93 for the company and are anticipating that the company will post ($0.11) EPS for the current quarter, according to Zacks. Zacks has also given DelMar Pharmaceuticals an industry rank of 108 out of 255 based on the ratings given to its competitors.

Several equities research analysts have recently issued reports on the stock. HC Wainwright set a $12.00 price objective on shares of DelMar Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, May 23rd. ValuEngine raised shares of DelMar Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, June 2nd.

NASDAQ:DMPI traded up $0.02 during trading hours on Thursday, hitting $0.70. The stock had a trading volume of 231,400 shares, compared to its average volume of 414,317. DelMar Pharmaceuticals has a one year low of $0.64 and a one year high of $2.84. The company has a market capitalization of $15.24 million, a PE ratio of -0.95 and a beta of 1.45.

DelMar Pharmaceuticals (NASDAQ:DMPI) last issued its earnings results on Tuesday, May 15th. The company reported ($0.13) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.10) by ($0.03). equities analysts forecast that DelMar Pharmaceuticals will post -0.54 earnings per share for the current year.

DelMar Pharmaceuticals Company Profile

DelMar Pharmaceuticals, Inc, a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients who have failed to respond to modern therapy. Its product candidate includes VAL-083, a small-molecule chemotherapeutic agent, which is in Phase III study for the treatment of recurrent glioblastoma multiforme.

Get a free copy of the Zacks research report on DelMar Pharmaceuticals (DMPI)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for DelMar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DelMar Pharmaceuticals and related companies with's FREE daily email newsletter.

Leave a Reply